Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
 - EconoTimes)
RALEIGH, N.C., March 31, 2016 -- PRA Health Sciences (PRA) (NASDAQ:PRAH), is pleased to announce that it received a “Highly Commended” designation by Vaccine Industry Excellence (ViE) for Best Contract Research Organization. PRA was originally named a finalist in the category based on industry nominations. Finalists submitted a detailed questionnaire about their vaccine capabilities which was then blinded, reviewed, and rated by a panel of judges.
“This is a great honor,” said Frank Hijek, PRA Senior Vice President, Strategic Drug Development. “By combining PRA’s therapeutic expertise and experience with proven strategies and innovative approaches, we are redefining vaccine clinical research. This recognition speaks to our commitment to accelerate vaccine development.”
PRA’s vaccine experience includes Phase I - Phase IV adult and pediatric studies involving nearly 213,000 study participants at more than 3,000 sites around the world. In the past five years, PRA teams have participated in over 140 vaccine studies; these include studies that led to the approval of six vaccines that are currently on the market. More information about PRA’s Vaccine Solutions group can be found at www.pravaccinesolutions.com.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.
INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463
